The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,…
Omomyc
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
